KLK2 and prostate cancer: In LNCaP hormone-sensitive metastatic prostate cancer cells genetically modified to express different amounts of TRPM8 (Alaimo et al, 2020), TRPM8 expression paralleled KLK3 (PSA) expression at both RNA and protein levels, while leaving unchanged other canonical AR transcriptional targets, such as KLK2, NKX3.1 and TMPRSS2 (Figs. 1A and EV1A).